|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0020792,
umls-concept:C0025202,
umls-concept:C0030956,
umls-concept:C0039195,
umls-concept:C0085358,
umls-concept:C0577559,
umls-concept:C1332717,
umls-concept:C1413244,
umls-concept:C1522240,
umls-concept:C1706438,
umls-concept:C2698600
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1995-1-30
|
|
pubmed:abstractText |
We and others have previously reported that melanoma-specific, cytotoxic T lymphocytes (CTL) define a minimum of six class I-presented peptide epitopes common to most HLA-A2+ melanomas. Here we show that three of these peptide epitopes are coordinately recognized by a CTL clone obtained by limiting dilution from the peripheral blood of an HLA-A2+ melanoma patient. Tandem mass spectrometry was used to characterize and sequence one of these three naturally processed melanoma peptides. One of the potential forms of the deduced peptide sequence (XXTVXXGVX, X = I or L) matches positions 32-40 of the recently identified melanoma gene MART-1/Melan-A. This peptide (p939; ILTVILGVL) binds to HLA-A2 with an intermediate-to-low affinity and is capable of sensitizing the HLA-A2+ T2 cell line to lysis by CTL lines and clones derived from five different melanoma patients. A relative high frequency of anti-p939-specific effector cells appear to be present in situ in HLA-A2+ melanoma patients, since p939 is also recognized by freshly isolated tumor infiltrating lymphocytes. p939 represents a good candidate for the development of peptide-based immunotherapies for the treatment of patients with melanoma.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-1402688,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-1549590,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-1607654,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-1671580,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-1840703,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-1868040,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-2406452,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-2469723,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-2479838,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-2481593,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-2529220,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-3722826,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-3872841,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-6167544,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-7510746,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-7513441,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-7516411,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-7681084,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-7684681,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-7690811,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-7691962,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-7694286,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-8006576,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-8006593,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-8018207,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-8113684,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-8124708,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-8125142,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-8164742,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-8169004,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-8170938,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-8175386,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-8398980,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7807017-8459226
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0022-1007
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
181
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
363-8
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:7807017-Amino Acid Sequence,
pubmed-meshheading:7807017-Antigens, Neoplasm,
pubmed-meshheading:7807017-CD8-Positive T-Lymphocytes,
pubmed-meshheading:7807017-Clone Cells,
pubmed-meshheading:7807017-Epitope Mapping,
pubmed-meshheading:7807017-HLA-A2 Antigen,
pubmed-meshheading:7807017-Humans,
pubmed-meshheading:7807017-Mass Spectrometry,
pubmed-meshheading:7807017-Melanoma,
pubmed-meshheading:7807017-Molecular Sequence Data,
pubmed-meshheading:7807017-Peptides,
pubmed-meshheading:7807017-T-Lymphocytes, Cytotoxic
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes.
|
|
pubmed:affiliation |
Istituto Nazionale Tumori, Milan, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
